Systemic delivery of protein nanocages bearing CTT peptides for enhanced imaging of MMP-2 expression in metastatic tumor models

Int J Mol Sci. 2014 Dec 24;16(1):148-58. doi: 10.3390/ijms16010148.

Abstract

Matrix metalloproteinase 2 (MMP-2) in metastatic cancer tissue, which is associated with a poor prognosis, is a potential target for tumor imaging in vivo. Here, we describe a metastatic cancer cell-targeted protein nanocage. An MMP-2-binding peptide, termed CTT peptide (CTTHWGFTLC), was conjugated to the surface of a naturally occurring heat shock protein nanocage by genetic modification. The engineered protein nanocages showed a binding affinity for MMP-2 and selective uptake in cancer cells that highly expressed MMP-2 in vitro. In near-infrared fluorescence imaging, the nanocages showed specific and significant accumulation in tumor tissue after intravenous injection in vivo. These protein nanocages conjugated with CTT peptide could be potentially applied to a noninvasive near-infrared fluorescence detection method for imaging gelatinase activity in metastatic tumors in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • HT29 Cells
  • Humans
  • Male
  • Matrix Metalloproteinase 2 / genetics
  • Matrix Metalloproteinase 2 / metabolism*
  • Mice
  • Mice, Inbred BALB C
  • Nanoconjugates
  • Neoplasm Metastasis
  • Neoplasms / metabolism*
  • Optical Imaging
  • Peptides, Cyclic / administration & dosage
  • Peptides, Cyclic / pharmacokinetics*
  • Protein Binding
  • Tissue Distribution

Substances

  • CTTHWGFTLC peptide
  • Nanoconjugates
  • Peptides, Cyclic
  • MMP2 protein, human
  • Matrix Metalloproteinase 2